Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
- PMID: 39113657
- PMCID: PMC11694107
- DOI: 10.3324/haematol.2024.285416
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
Figures

References
-
- Ribera J-M, Oriol A, Morgades M, et al. . Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595-1604. - PubMed
-
- Ribera J-M, Morgades M, Ciudad J, et al. . Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879-1894. - PubMed
-
- Degryse S, de Bock CE, Cox L, et al. . JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-3100. - PubMed
LinkOut - more resources
Full Text Sources